Gitnux/Report 2026

Biomed Industry Statistics

The global medical-technology market reached approximately $650 billion in 2025, explore the figures behind growth, companies, and trends shaping biomed through 2026.
309Statistics
106Sources
12Sections
1Visuals
48mRead
November 11, 2026Updated
Biomed Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published ·Updated
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The biomed industry at a glance

The biomedical industry is expanding across biotech, biopharma and medtech: global medical-technology revenue reached approximately $650 billion in 2025, up 11% year over year.

$650B[21]
Global medtech revenue, 2025
11%[21]
Medtech revenue growth, 2025
430,000+[22]
U.S. medtech jobs, 2025
€38.1B[91]
EU biotech GDP contribution, 2022
Market size
Global medical-technology revenue reached approximately $650 billion in 2025. In the United States, the medical-technology market was valued at $257 billion in 2024, according to AdvaMed.[21][64]
Forecast & CAGR
Global medtech revenue increased 11% in 2025, while first-half 2026 revenue rose 7.1% year over year to $325 billion. The European Commission reports that the EU biotechnology sector’s GDP contribution grew by approximately 7% per year on average between 2015 and 2024.[21][91]
Market share & regions
The United States was the largest national medtech market, valued at $257 billion in 2024. Asia-Pacific accounted for 21.0% of the global medical-device market in 2024, with an estimated value of about $109 billion.[64][92]
Segmentation
Biomedical activity spans pharmaceuticals and biotherapeutics, medical devices, diagnostics, vaccines, research and testing, and laboratory tools. In India’s 2025 biopharma distribution, biotherapeutics were valued at $24.36 billion, medical devices and diagnostics at $22.14 billion, and vaccines at $17.98 billion.[93]
Key players & concentration
The EU biotechnology sector is structurally fragmented: 47% of companies are small and medium-sized enterprises, 35% are microenterprises, and 18% are large companies. The sector included approximately 5,000 R&D-active biotechnology companies in the EU.[91]
Pricing
U.S. prescription-drug spending increased 7.9% to $467.0 billion in 2024. CMS projects retail prescription-drug spending to grow at an average annual rate of 5.7% during 2025–2034.[94]
Trends, drivers & challenges
Growth is being driven by AI-enabled diagnostics, robotics, structural-heart technologies, diabetes care and minimally invasive therapies. Key challenges include trade and supply-chain uncertainty, negative investor sentiment, long product-development cycles and pressure on drug affordability.[21][22][94]
Consumer behavior & competition
Medtech companies are expanding beyond hospitals into ambulatory surgery centers and direct-to-consumer or direct-to-patient channels. EY reported that 2025 growth was highly concentrated among commercial leaders, indicating a widening performance gap between leading and smaller companies.[21]
M&A
Medtech M&A value increased 160% in the first half of 2026 compared with the first half of 2025. In biotech, companies raised $20.6 billion in venture capital during 2025, while deals of at least $5 billion represented 59% of total deal spending in the 2026 EY review.[21]
Regulation
The FDA had authorized more than 1,600 AI-enabled medical devices in the United States as of September 2026. In the EU, the proposed European Biotech Act, COM(2025) 1022, is intended to strengthen biotechnology and biomanufacturing, with broader ecosystem measures planned for 2026.[1][91]
Latest news
In October 2026, OpenAI acquired biotechnology startup Orchestra and planned to integrate its team and technology into Rosalind, an AI platform for life-sciences researchers. The transaction illustrates the continuing convergence of artificial intelligence and biomedical research.[95]

02 Ranking

Top 10 Companies in the Biomed Industry

The leading companies in the biomed industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 10, 2026 · Next review December 10, 2026

Verdict

Boston Scientific stands out for minimally invasive cardiovascular and specialty devices because it reports more than 48 million patients treated each year, while Roche focuses on diagnostics and biotechnology since its Diagnostics Division recorded CHF 13.8 billion sales in 2025.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in cardiovascular devices

    Boston Scientific

    US

    Ranked #1 · 9.3 · Cardiovascular devices

    Why we picked it: Scale in minimally invasive cardiovascular and specialty devices is reflected in treating over 48 million patients annually.

    See in ranking ↓Visit bostonscientific.com ↗

  2. Leader in diagnostics and imaging

    Roche

    CH

    Ranked #2 · 9.2 · Diagnostics and imaging

    Why we picked it: Diagnostics, sequencing and pharmaceutical biotechnology are evidenced by CHF 13.8 billion Diagnostics Division sales in 2025.

    See in ranking ↓Visit roche.com ↗

  3. Leader in surgery and implantables

    Medtronic

    IE

    Ranked #3 · 9.1 · Surgery and implantables

    Why we picked it: Its implantable devices, surgery and patient monitoring span cardiac, surgical, neurological and diabetes technology lines.

    See in ranking ↓Visit medtronic.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the biomed industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Boston Scientific

Cardiovascular devices · US

9.3
2

Roche

Diagnostics and imaging · CH

9.2
3

Medtronic

Surgery and implantables · IE

9.1
4

Siemens Healthineers

Diagnostics and imaging · DE

9.1
5

Johnson & Johnson

Surgery and implantables · US

9.1
6

Stryker

Orthopaedics, surgical and neurovascular devices · US

8.7
7

Olympus

Endoscopy and surgical-intervention systems · JP

8.7
8

Thermo Fisher Scientific

Life-science tools, diagnostics and biopharma production · US

8.7
9

Agilent Technologies

Laboratory instruments and diagnostics technologies · US

8.6
10

Zimmer Biomet

Orthopaedic implants and surgical technologies · US

8.1

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 10, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 10). Top 10 companies in the biomed industry. In Biomed Industry Statistics. Gitnux. https://gitnux.org/biomed-industry-statistics/#top-companies

report visual · Projection

Employment in pharmaceutical research and development in Europe

Employment in pharmaceutical research and development in Europe grew from 88K in 2000 to 130K in 2024.

88.4K count
Start
+1.62%
CAGR · 24y
130K count
Projected
20002024
source-verifiedefpia.eu2024

04 Statistics

Technology & Innovation

AI device authorization keeps rising, with 1,524 AI-enabled medical devices included on the FDA list as of June 2026 and 76.6% radiology devices in the analyzed dataset.

AI in the biomed industry

  • 1,524 AI-enabled medical devices were included on the FDA list as of June 2026.[1]
  • 46% of large biopharma companies said they could attract and hire skilled AI talent in 2024.[2]
  • 37.22% of 1,679 AI-related biopharmaceutical venture-capital deals from 2010 to 2024 focused on biotechnology or pharmaceuticals.[3]
  • 67% of large biopharma companies with at least 1,000 employees had adopted AI/ML in 2024.[2]
  • Over 1,600 AI-enabled medical devices had been authorized for marketing in the United States by September 2026.[1]
  • 76.6% of FDA-authorized AI-enabled medical devices in the analyzed dataset were radiology devices.[3]

Automation in the biomed industry

  • 91% of life-sciences professionals surveyed in 2024 viewed operator-free filling as the future of drug-product manufacturing.[4]
  • 57% of biopharmaceutical survey respondents planned to automate sample-workflow tracking in 2026.[5]
  • 418 respondents participated in the 2023 ISPE Pharma 4.0 digital-transformation survey covering pharmaceutical-industry automation and digital maturity.[6]
  • 20 biologics drug-substance manufacturing plants participated in McKinsey’s digital-maturity assessment conducted between 2021 and 2024.[7]
  • 39% of midsized biopharmaceutical companies relied on manual laboratory processes in 2026.[5]
  • 17 batches per year was the top-quartile bioreactor throughput for biologics drug-substance manufacturing sites in McKinsey’s database.[7]

Digital Transformation in the medical devices sector (sector benchmark)

  • Across medtech and IVD professionals worldwide, 89% said their company had implemented or planned to implement AI or digital solutions in its product range in 2020.[8]
  • Across medtech and IVD professionals worldwide, 87% said their company had implemented or planned to implement AI or digital solutions in regulatory or quality-management systems in 2020.[8]
  • Across medtech companies, 29% met or exceeded their digital-transformation targets with sustainable change in 2021, according to BCG’s global survey.[9]
  • Across medtech companies, 36% achieved limited value and no sustainable change from digital transformation in 2021.[9]
  • Across medtech manufacturing executives, 64% highly prioritized digitizing manufacturing in a 2022 survey.[10]
  • Across medtech companies, 35% created value but failed to meet all digital-transformation targets in 2021.[9]

Technology Adoption in the medical devices sector (sector benchmark)

  • Across healthcare industrial-ecosystem SMEs in Europe, 31.0% already used cloud technologies in 2023.[11]
  • Across healthcare industrial-ecosystem SMEs in Europe, 13.7% already used artificial intelligence in 2023.[11]
  • Among emerging medtech companies, 62% had adopted electronic trial-master-file systems, compared with 89% of enterprise and global companies in the 2025 benchmark.[12]
  • Across healthcare industrial-ecosystem SMEs in Europe, 17.3% already used robotics in 2023.[11]
  • Across healthcare industrial-ecosystem SMEs in Europe, 8.6% already used remote patient-monitoring technologies in 2023.[11]
  • Among emerging medtech companies, 38% had adopted clinical-trial-management systems, compared with 72% of enterprise and global companies in the 2025 benchmark.[12]

Cloud Computing in the medical devices sector (sector benchmark)

  • Across surveyed medtech organizations, 31% managed all postmarket-surveillance processes with cloud-based technology in 2025.[12]
  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 66% reported that 50%–74% of infrastructure was in the cloud in 2022.[13]
  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 21% reported that 75%–100% of infrastructure was in the cloud in 2022.[13]
  • Across surveyed medtech organizations, 33% reported reliable enterprise-wide use of cloud-based technologies in 2025.[12]

Big Data in the medical devices sector (sector benchmark)

  • Across medtech companies surveyed by Model N, nearly 70% already used or planned to use data and analytics in 2023.[14]
  • Across medtech and biopharma companies surveyed in 2018, 67% of medtech firms invested in data analytics for reporting.[15]

05 Statistics

Data & Analytics

Data visibility and integration gaps appear in launch execution, including 48% of biopharmas facing data-integration challenges during their most recent launch in 2026.

Business intelligence in the biomed industry

  • 83% of biopharma respondents considered a connected data ecosystem integrated with CRM important for launch readiness in 2026.[12]
  • 67% of biopharmas using AI for field activation delivered alerts through CRM in 2026.[12]
  • 30% of biopharma launch respondents struggled to identify the right data sources in 2026.[12]
  • 98% of biopharma brands used at least two data providers for commercial activities in 2026.[12]
  • 43% of biopharma launch respondents cited data latency or lack of real-time visibility as a challenge in 2026.[12]
  • 27% of biopharma launch professionals worked in commercial analytics, business intelligence or data science in 2026, across surveyed companies globally.[12]

Data analytics in the biomed industry

  • 64% of biopharma launch respondents said they lacked all foundational data needed for success during their most recent launch in 2026.[12]
  • 63% of biopharma organizations used AI for marketing during product launches in 2026.[12]
  • 53% of biopharma organizations used AI for competitive analysis during product launches in 2026.[12]
  • 61% of biopharma launch respondents reported difficulty translating analytics into rapid field action in 2026.[12]
  • 48% of biopharmas faced data-integration challenges during their most recent launch in 2026.[12]
  • 43% of small and midsize biopharma companies were pursuing big data and analytics or data science in 2024.[16]

Data Quality in the medical devices sector (sector benchmark)

  • 45.9% of healthcare-sector business partners identified data quality as a major challenge in managing digital product information in the 2021 survey.[17]
  • 73% of medical-device professionals using literature-review software trusted their data quality, compared with 38% using spreadsheets, in a global survey; survey year not stated.[18]
  • 56% of medical-device companies used non-validated general-purpose tools for clinical data collection in the 2024 MedTech industry survey.[19]
  • 51% of medical-device companies still managed postmarket-surveillance processes and data manually or partially manually in the 2025 benchmark survey.[12]
  • 60% of medical-device professionals using literature-review software reported data traceability, compared with 4% using spreadsheets, in a global survey; survey year not stated.[18]

Data Governance in the medical devices sector (sector benchmark)

  • More than 30% of healthcare-sector business partners had no clear formal data-governance guidelines in the 2021 survey.[17]
  • More than 72% of healthcare-sector business partners had not established a product-master-data system reflecting data governance in the 2021 survey.[17]
  • 62.3% of healthcare-sector business partners identified creating a central data master as a single source of truth as the greatest digital-product-information challenge in 2021.[17]
  • 31.4% of healthcare-sector business partners had a digital-asset-management system for storing images and product data sheets in the 2021 survey.[17]

KPIs in the biomed industry

  • 59% of U.S. pharmaceutical companies reported omnichannel integration for medical-information content in the 2024 phactMI survey.[3]
  • 62% of responding U.S. pharmaceutical medical-information teams were organized by therapeutic area in the 2024 phactMI survey.[3]
  • 52% of biopharma and medtech companies did not holistically measure leading and lagging indicators in 2025.[20]
  • 35% of biopharma organizations used AI for performance tracking during product launches in 2026.[12]
  • 97% of biopharma and medtech leaders agreed that omnichannel was critical for success in 2025.[20]
  • 31% of U.S. pharmaceutical companies used digital metrics to inform content or channel strategy in the 2024 phactMI survey.[3]

06 Statistics

Strategy & Growth

Industry output and deal activity quantify expansion, including $650 billion in global medical-technology revenue in 2025 and $232 billion in biotechnology-industry revenue in 2025.

Growth in the biomed industry

  • $584 billion was generated by the global medical-technology industry in 2025.[21]
  • $232 billion was generated in biotechnology-industry revenue in 2025, up 13% from 2024.[21]
  • $3.19 trillion in total economic output was generated by the U.S. bioscience industry in 2025.[22]
  • $650 billion was generated in global medical-technology revenue in 2025, representing 11% growth.[21]
  • 6% to 7% revenue growth was forecast for leading medical-technology companies in 2025.[21]
  • 156,000 business establishments operated in the U.S. bioscience industry in 2025, up 22% from 2021.[22]

Differentiation in the biomed industry

  • 10.1% was the increase in U.S. bioscience research-and-development spending from 2022 to 2023.[22]
  • 11% of 2024 biopharma partnerships covered immunology and inflammation.[23]
  • 10% of 2024 biopharma partnerships covered cardiovascular diseases.[23]
  • 47% of 2024 biopharma partnerships covered oncology, according to a partnership analysis.[23]
  • 85% of 2024 biopharma partnerships were early-stage deals, according to the partnership-stage analysis.[23]
  • 14% of 2024 biopharma partnerships covered metabolic diseases.[23]

Mergers and acquisitions in the biomed industry

  • 125 biopharma M&A deals were recorded in 2023, with $160 billion in total value.[24]
  • 52 strategic research-and-development collaborations were recorded among pharmaceutical-company deals in 2023.[25]
  • 153 pharmaceutical-company deals were recorded in the first half of 2024 dataset.[25]
  • 95 licensing deals were recorded among pharmaceutical-company deals in 2023.[25]
  • 28 corporate acquisitions were recorded among pharmaceutical-company deals in 2023.[25]
  • 14 product acquisitions were recorded among pharmaceutical-company deals in 2023.[25]

Strategic partnerships in the biomed industry

  • 434 research-and-development partnerships were secured by biopharma therapeutics and platform companies in 2024.[24]
  • 89 early-stage collaborations were recorded in 2024, representing 89% of collaborations.[23]
  • $610 million was the median total deal value for biopharma licensing agreements in 2024.[23]
  • 100 collaboration agreements were announced in 2024, compared with 87 licensing agreements.[23]
  • $182.5 billion was the total value of 2024 biopharma therapeutics and platform research-and-development partnerships.[24]
  • 30 biopharma licensing deals with upfront payments above $100 million were signed in 2024.[26]

07 Statistics

People & Workforce

Workforce scale and operating capacity show through hiring and turnover metrics, including a 6.1% voluntary employee turnover rate at AstraZeneca in 2024.

Hiring in the biomed industry

  • 1,700 external hires were made at AstraZeneca’s global hubs in Mississauga, Lisbon, Barcelona and Warsaw in 2024.[27]
  • One-third of surveyed U.S. life-sciences companies said recent hires represented less than 20% of their total workforce in 2023–2024.[28]
  • 560 new employees were recruited by Novartis in Slovenia in 2024, mainly in production and quality.[29]
  • 22,500 employees were hired by AstraZeneca in 2022, including 7,700 internal and 14,800 external hires.[27]
  • 5,800 internal promotions were made by AstraZeneca during 2024, supporting internal talent acquisition.[27]

Employee retention in the biomed industry

  • 7% was Novartis’s voluntary employee turnover rate in 2025, compared with 6% in 2024.[29]
  • 13% was Novartis’s total employee turnover rate in 2025, compared with 12% in 2024.[29]
  • 19.12% was Sun Pharmaceutical’s total employee turnover rate in fiscal 2024, covering 6,864 employees.[30]
  • 6.1% was AstraZeneca’s voluntary employee turnover rate in 2024.[31]
  • 8.2% was AstraZeneca’s voluntary turnover rate among recent hires in 2024.[31]

Remote Work in the medical devices sector (sector benchmark)

  • Remote medical device and diagnostics professionals reported a median salary of $142,000 in 2023, according to an industry salary survey.[32]
  • Remote medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[32]
  • Remote medical device and diagnostics employees worked an average of 41.5 hours per week in 2023, compared with 43 hours for office-based employees.[32]
  • About 50% of medical device and diagnostics professionals worked fully remotely in 2023, based on 226 usable survey responses in the United States.[32]

Hybrid Work in the medical devices sector (sector benchmark)

  • Hybrid medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[32]
  • Hybrid medical device professionals reported a median salary of $150,000 in 2026, compared with $140,000 for remote and $116,000 for in-office professionals.[32]
  • Hybrid medical device and diagnostics professionals reported a median salary of $135,000 in 2023, according to an industry salary survey.[32]
  • Hybrid medical device and diagnostics professionals represented about 40% of respondents in MD+DI’s 2023 salary survey, covering 226 usable responses.[32]

Upskilling in the biomed industry

  • 4,391,124 total learning hours were delivered by AstraZeneca employees in 2024.[31]
  • 127,115 training modules were completed by Sanofi employees in 2025.[33]
  • 2,212 Almirall employees participated in training during 2024.[34]
  • 3,004,271 total training hours were recorded by Sanofi in 2025.[33]
  • 36 hours was Almirall’s average employee training time in 2024.[34]

Employee Engagement in the medical devices sector (sector benchmark)

  • Medical devices organizations had a median employee net promoter score of 14 in Culture Amp’s 2026 benchmark.[35]
  • In medical devices, 23% of employees disagreed that their total compensation was fair relative to similar roles at other companies in the 2026 benchmark.[35]
  • In medical devices, 91% of employees agreed they understood how their work contributed to company goals in benchmark data collected through June 2026.[35]
  • In medical devices, 73% of employees were engaged in benchmark data collected from July 2025 through June 2026, predominantly across Northern America, Oceania, Europe and Asia.[35]

DEI in the biomed industry

  • 15% of the Massachusetts biopharma workforce identified as people of color in 2021.[36]
  • 17.1% of Pfizer’s U.S. analyst-and-below hires were Black or African American in 2024.[37]
  • 46.8% of Novartis Slovenia’s employees were women in 2024.[29]

08 Statistics

Customer & Sales

Adoption of digital engagement is measurable, with 50% of HCPs preferring digital interactions over in-person interactions with pharma companies in 2025.

Customer experience in the biomed industry

  • Companies with more effective pharma-representative engagement achieved a 22% higher Net Promoter Score in the 2025 HCP survey.[38]
  • -57% was the Net Promoter Score for the lowest-performing pharma companies in the 2025 U.S. HCP survey.[38]
  • 50% of HCPs preferred digital interactions over in-person interactions with pharma companies in 2025.[38]
  • 15.6 was the 2024 overall customer-experience score for surveyed life-science suppliers, up from 15.5 in 2023.[39]
  • -10% was the average Net Promoter Score for pharma companies among more than 700 U.S. healthcare providers in 2025.[38]

Customer retention in the biomed industry

  • 12 emails per month from one pharma brand was the level at which surveyed HCPs said they would opt out regardless of content usefulness.[38]
  • 26% of medtech organizations had fully automated, always-on post-purchase engagement and retention in 2025.[40]
  • 17% of medtech organizations had fully automated, always-on reactivation of dormant customers in 2025.[40]
  • 5.0% was the three-month retention rate at the 75th percentile for digital healthcare products in 2025.[41]
  • 10.6% was the three-month retention rate at the 90th percentile for digital healthcare products in 2025.[41]

Customer acquisition in the biomed industry

  • More than 15% revenue uplift was associated with effective omnichannel execution in surveyed biopharma and medtech companies in 2025.[20]
  • Twice as many HCPs preferred pharma representatives to bring practice knowledge rather than product knowledge in the 2025 commercialization research.[38]
  • 3.6% was the 75th-percentile acquisition rate for digital healthcare products in 2025.[41]
  • 10%–15% of advertising and promotion budgets were allocated to omnichannel activity by surveyed biopharma and medtech companies in 2025.[20]
  • 5%–10% was the reported top-line brand-sales lift from dynamic, targeted pharma sales calls.[38]

Customer loyalty in the biomed industry

  • 32.5 was the 2024 life-science supplier score for product integrity in the BioInformatics customer-experience study.[39]
  • 1.7 was the 2024 life-science supplier score for product selection in the BioInformatics customer-experience study.[39]
  • 36.7 was the 2024 life-science supplier score for satisfaction and loyalty in the BioInformatics customer-experience study.[39]
  • 16.8 was the 2023 life-science supplier score for service provided in the BioInformatics customer-experience study.[39]
  • 1.8 was the 2023 life-science supplier score for product selection in the BioInformatics customer-experience study.[39]

Lead generation in the biomed industry

  • 21% of scientific-sales and marketing professionals identified events as their leading source of leads in 2026.[42]
  • 77.7% of companies with marketing teams of one to five people did not score leads in the 2025 scientific-marketing survey.[43]
  • 22% of science, healthcare and engineering companies reported decreased sales inquiries in 2024.[43]
  • 29% of scientific-sales and marketing professionals identified inbound activity as their leading source of leads in 2026.[42]
  • 48% of science, healthcare and engineering companies reported increased sales inquiries in 2024.[43]

09 Statistics

Marketing & Brand

Direct-to-consumer and digital channel spend remain quantified, including $10.8 billion spent on U.S. direct-to-consumer pharmaceutical advertising in 2024.

Marketing in the biomed industry

  • One in three dollars of U.S. pharmaceutical direct-to-consumer advertising spend went to immunology in 2024.[44]
  • 4.4% was the median advertising expense as a percentage of revenue for pharmaceutical companies in 2019.[45]
  • $10.8 billion was spent by U.S. drug companies on direct-to-consumer pharmaceutical advertising in 2024.[46]
  • 10% was the year-over-year growth in pharmaceutical advertising expense in 2023.[45]
  • 4.7% was the projected year-over-year growth in pharmaceutical advertising expense in 2026.[45]

Digital marketing in the biomed industry

  • 27.3% of U.S. pharmaceutical and medicine manufacturers’ advertising spend was digital in 2023.[47]
  • 88% of U.S. healthcare and pharmaceutical digital advertising spending was projected to come from pharma in 2024.[48]
  • 30.8% of U.S. pharmaceutical and medicine manufacturers’ advertising spend was forecast to be digital in 2025.[47]
  • $19.45 billion was projected to be spent on U.S. pharmaceutical online marketing in 2024.[48]
  • 29.2% of U.S. pharmaceutical and medicine manufacturers’ advertising spend was digital in 2024.[47]

Branding in the biomed industry

  • $5.554 billion was the 2024 brand value of Novartis.[49]
  • $5.769 billion was the 2024 brand value of Bayer.[49]
  • $6.107 billion was the 2024 brand value of Merck & Co.[49]
  • $13.361 billion was the 2024 brand value of Johnson & Johnson, the world’s most valuable pharmaceutical brand.[49]
  • $5.329 billion was the 2024 brand value of Novo Nordisk.[49]

Social media in the biomed industry

  • 7% of surveyed physicians preferred social-media channels for receiving information from pharmaceutical companies in 2024.[50]
  • 100% of pharmaceutical social-media posts in the cited review included the promoted drug’s purported benefits.[46]
  • 70% of surveyed pharmaceutical and healthcare advertising professionals planned to increase social-media spending in the second half of 2024.[51]
  • 4.00 was the ratio of public actions to pharmaceutical-company tweets in the non-COVID-19 communication channel.[3]
  • 12% was the average use of online social channels by pharmaceutical companies in 2024 in the Worldcom Digital Health Monitor.[51]

Influencer Marketing in the medical devices sector (sector benchmark)

  • 10% of healthcare and pharmaceutical marketers reported that they did not invest in creator or influencer marketing in 2026.[52]
  • 8% of healthcare and pharmaceutical marketers had dedicated but shrinking budgets for creator or influencer marketing in 2026.[52]
  • 8.57 million influencer posts about the health industry were published globally in 2023, across the platforms measured by Sprout Social.[53]
  • 29% of healthcare and pharmaceutical marketers had dedicated but flat budgets for creator or influencer marketing in 2026.[52]
  • 1.07% was the average engagement rate for health-industry influencer posts globally in 2023, across the platforms measured by Sprout Social.[53]

10 Statistics

Operations & Execution

Manufacturing and supply-chain digitization is tied to outcomes, including 61% of respondents aiming to increase production speed in biopharma operations.

Process optimization in the biomed industry

  • 6 to 12 months was the reported cycle-time range for releasing GMP drug substance from dose-limiting toxicity to first subject first dose across pharmaceutical modalities.[54]
  • 48% of 105 biopharma supply-chain leaders reported partially realized warehouse-operation efficiencies from digitalization investments in 2023.[55]
  • 33% of 105 biopharma supply-chain leaders expected to scale deep learning, machine vision or digital twins for process improvements within five years, according to a 2023 survey.[55]
  • 10% of respondents at 20 biologics drug-substance manufacturing plants reported using advanced analytics for regular improvement actions or real-time optimization, based on data collected from 2021 to 2024.[7]
  • 1,192 kilograms per kilogram of active pharmaceutical ingredient was the average mass intensity reported for continuous monoclonal-antibody processing, versus 2,348 kilograms per kilogram for batch processing.[56]

Operational efficiency in the biomed industry

  • 29.7% of respondents to the 2024 ISPE Pharma 4.0 survey identified complexity reduction as a driver of digital-transformation programs in pharmaceutical operations.[6]
  • 17 drug-substance batches per year was the top-quartile bioreactor throughput in McKinsey’s biologics manufacturing benchmark, compared with 14 batches at median sites.[7]
  • 2 to 4 years was the potential delay in site and equipment purchases enabled by flexible modular biopharma manufacturing setups.[20]
  • 61% of respondents in a pharmaceutical operational-excellence survey cited increasing production speed as a day-to-day manufacturing goal.[57]
  • 7% was the reported increase in pharmaceutical CDMO batch prices since 2020, according to a 2026 industry report.[57]

Quality management in the biomed industry

  • 8.0% of 163 Chinese pharmaceutical inspections received an official-action-indicated outcome in fiscal year 2025.[1]
  • 17.9% of 207 Indian pharmaceutical inspections received an official-action-indicated outcome in fiscal year 2025.[1]
  • 15.0% of 40 Canadian pharmaceutical inspections received an official-action-indicated outcome in fiscal year 2025.[1]
  • 27.6% of Chinese pharmaceutical inspections received no-action-indicated outcomes in fiscal year 2025.[1]
  • 1,309 FDA pharmaceutical inspections in fiscal year 2025 produced outcomes of 22% no action indicated, 60% voluntary action indicated and 18% official action indicated.[1]

Supply chain in the biomed industry

  • 33% of 105 biopharma supply-chain leaders said their organizations were attempting to completely transform their supply chains using digital technologies in 2023.[55]
  • 5.96 out of 10 was the average global biopharma resilience score in 2025, down from 6.08 in 2023 and 6.60 in 2021.[57]
  • 41% of 105 biopharma supply-chain leaders reported partially realized improved workforce safety, productivity and performance from digitalization investments in 2023.[58]
  • 50% of 105 biopharma supply-chain leaders reported partially realized better risk sensing to avoid supply-chain disruptions from digitalization investments in 2023.[58]
  • 94.5% was the average pharmaceutical customer-service level in the 2014 Kearney Pharma Supply Chain Panel.[59]

Outsourcing / Offshoring in the medical devices sector (sector benchmark)

  • 11.4% was the year-over-year growth rate of the global medtech outsourcing market in 2023.[60]
  • $81.5 billion was the global medtech outsourcing market in 2023, covering contract development and manufacturing organizations (CDMOs).[60]
  • $18.5 billion was the European medtech CDMO market in 2023.[60]
  • 335 U.S. medical device contract manufacturers were identified in 2022, up from 314 in the prior registry.[60]
  • More than half of 59 global medtech CDMO transactions in 2023 had cross-border characteristics.[60]

11 Statistics

Finance & Pricing

Pricing pressure and margin changes show up in device and diagnostics examples, including Veracyte’s average selling price increase of 4% for diagnostic testing in 2024.

Pricing strategy in the biomed industry

  • 4% was Veracyte’s average selling price increase for diagnostic testing in 2024, alongside a 23% increase in test volume.[61]
  • $411 was Exagen’s trailing 12-month average selling price per AVISE CTD test at the end of 2024, up $75 year over year.[61]
  • 3.5x greater net price increase was realized by medium-sized medtech companies with $500 million–$1 billion in revenue than the survey comparison group.[62]
  • 40% was the two-year increase in Exagen’s average selling price for its AVISE CTD diagnostic test through the end of 2024.[61]
  • 5.6% was Abbott Core Laboratory sales growth in 2024 excluding foreign exchange, supported by testing volume and price increases.[61]

Cost reduction in the biomed industry

  • 4 percentage points was Bio-Techne’s total gross-margin improvement in fiscal 2024, helped by targeted price increases and lower shipping costs.[61]
  • 25 basis points was Danaher’s 2024 operating-margin impact from lower sales and product mix, net of operational and administrative cost improvements in Life Sciences.[61]
  • 0.5 percentage points was Bio-Rad’s 2024 Clinical Diagnostics gross-margin improvement from favorable product mix and cost-control measures.[61]
  • 2.5% of Danaher Biotechnology segment sales growth in 2024 came from price increases, helping offset demand pressures.[61]
  • 5% was the decline in the global biotech workforce in 2024 as companies cut costs and narrowed programs.[21]

Profitability in the biomed industry

  • 18.8% was Johnson & Johnson’s consolidated earnings-before-tax margin in 2024.[61]
  • 28.6% was Danaher’s adjusted operating-profit margin in 2024.[61]
  • 16% was Veracyte’s 2024 increase in operating income, reaching $16.1 million.[61]
  • 53.7% was Bio-Rad’s consolidated gross margin in 2024, compared with 53.4% in 2023.[61]
  • 58.2% was the gross margin of the unnamed life-science products company in fiscal 2024, compared with 58.9% in fiscal 2023.[61]

Financial planning in the biomed industry

  • 6.8% was the 2024 year-over-year revenue growth of public U.S. and European biotech companies, reaching $205.4 billion.[21]
  • $4.31 million was the average 2024 capital raise reported per Alberta biotechnology company surveyed by BioAlberta.[63]
  • 644 biotech financing rounds occurred in 2024, averaging $36 million per round.[21]
  • 12 months was the average R&D cash runway reported by surveyed Alberta biotechnology and medical-technology companies in 2025.[63]
  • 52% of Texas public biotech companies had insufficient cash to maintain operations for more than one year in the EY 2024 analysis.[21]

12 Statistics

Product & Service

Service and quality-system signals appear in recall and servicing data, including 333 biologics recalls recorded by the U.S. FDA in fiscal year 2024.

Product development in the biomed industry

  • More than $20 billion is invested annually in research and development by the U.S. medical technology industry.[64]
  • 6%–8% of medical technology company revenue is channeled into R&D in the United States.[64]
  • 28.8% of pharmaceutical R&D investment was allocated to Phase III clinical trials, based on 2022 industry data.[65]
  • 48.4% of pharmaceutical R&D investment was allocated to clinical trials, based on 2022 industry data.[65]
  • More than 900,000 participants were involved in U.S. biopharmaceutical-industry clinical trials in 2023.[66]

Product lifecycle in the biomed industry

  • 333 biologics recalls were recorded by the U.S. FDA in fiscal year 2024.[67]
  • The FDA MAUDE database contains manufacturer medical-device reports dating from August 1996.[1]
  • The top 10 vaccine manufacturers accounted for 78% of global vaccine doses in 2024.[68]
  • The FDA medical-device recall database contains classified recalls dating back to November 1, 2002.[1]
  • The top 10 vaccine manufacturers accounted for 84% of global vaccine financial value in 2024.[68]

After-sales in the biomed industry

  • 7.8% of total service-parts cost was spent on repeat replacements six months after the initial replacement in the average organization.[69]
  • 34 of 130 sampled medical-device servicers were captured by the industry-code search used in the FDA analysis.[1]
  • 4,791 U.S. firms were identified in an FDA search of medical-device servicing businesses using relevant industry classifications.[1]
  • 4.9% was the repeat-part-replacement rate for top-performing organizations six months after an initial replacement.[69]
  • 8.3% was the average repeat-part-replacement rate six months after an initial replacement in Aquant’s 2025 medical-device service analysis.[69]

Value proposition in the biomed industry

  • 30% of the U.S. medtech market was estimated to rely on imports in 2024–2025.[64]
  • €3.80 was the estimated return for every €1 invested in respiratory medicines in Europe between 2014 and 2024.[65]
  • 150,000 U.S. medtech jobs were estimated to be tied to exports in 2024–2025.[64]
  • €66 billion was the total estimated social, economic and hospital-cost benefit generated by €11.67 billion invested in new medicines in Europe between 2014 and 2024.[65]
  • $28 billion of U.S. medtech exports went to the European Union in 2024.[64]

13 Statistics

Sustainability & Ethics

ESG governance and operational footprints are measured, including 9% of European biotechnology and pharmaceutical companies having climate targets validated in 2024.

Sustainability in the biomed industry

  • 43% of AbbVie sites held ISO 50001 energy-management certification in 2024.[70]
  • 9% of European biotechnology and pharmaceutical companies had climate targets validated by the Science Based Targets initiative in 2024.[71]
  • 13% was AstraZeneca’s reduction in waste versus its 2015 baseline in 2024.[27]
  • 24% of European biotechnology and pharmaceutical companies reported conducting an energy audit during the previous three years in 2024.[71]
  • 23% was AstraZeneca’s reduction in water use versus its 2015 baseline in 2024.[27]

ESG in the biomed industry

  • 80 was the 2024 average score for operation of governance bodies among 86 European biotechnology and pharmaceutical companies.[71]
  • 71 was the 2024 average ESG score for minority-shareholder dilution risk in the European biotechnology and pharmaceutical sector.[71]
  • 60 was the 2024 average ESG score for business ethics among European biotechnology and pharmaceutical companies.[71]
  • 57 was the 2024 average ESG score for executive-officer compensation in the European biotechnology and pharmaceutical sector.[71]
  • 66 was the 2024 average ESG score for cybersecurity among European biotechnology and pharmaceutical companies.[71]

Ethics in the biomed industry

  • 71% was the median rate at which patient trials reported results or shared a clinical-study-report synopsis in the same pharmaceutical-company study.[72]
  • 43% of Indian pharmaceutical organizations had dedicated ESG or sustainability committees as of 2024, a governance indicator linked to ethical oversight.[73]
  • 190 million animals are estimated to be killed annually in laboratory testing worldwide, a major ethical issue for pharmaceutical research and development.[74]
  • 39% of industry sponsors met an 80% clinical-trial disclosure threshold in the transparency analysis.[3]
  • 74% was the mean disclosure rate for industry-sponsored clinical trials in a global analysis of registered trials.[3]

CSR in the biomed industry

  • 27% of North American pharmaceutical companies disclosed independent verification of sustainability data in the SGS review.[75]
  • 53 of 66 pharmaceutical reporting organizations disclosed ESG and sustainability data through a stand-alone report in an industry reporting review.[75]
  • 23 was the 2024 average score for skills development among European biotechnology and pharmaceutical companies.[71]
  • 15 was the 2024 average score for biodiversity among European biotechnology and pharmaceutical companies.[71]
  • 50 was the 2024 average score for CSR policy and extra-financial issues among European biotechnology and pharmaceutical companies.[71]

Circular economy in the biomed industry

  • 50,000 kilograms of laboratory plastic were recycled at Pfizer’s Andover facility in 2024.[30]
  • 2,326.8 tonnes of Recordati waste were diverted from disposal through recovery operations in 2024.[76]
  • 14.5% was Hisamitsu Pharmaceutical’s recycling rate in fiscal 2024.[77]
  • 88% was the recycling rate across BioPharmaChem Ireland member sites in 2026.[78]
  • 6.3 tonnes was Hisamitsu Pharmaceutical’s final waste-disposal volume in fiscal 2024.[77]

Carbon footprint in the biomed industry

  • 25% of pharmaceutical-company emissions are attributed roughly to active-pharmaceutical-ingredient manufacturing.[7]
  • 21.7% was AbbVie’s reduction in absolute total hazardous and non-hazardous waste versus 2015 in 2024, an emissions-relevant operational measure.[70]
  • 91% was LEO Pharma’s share of renewable electricity in 2023.[79]
  • Less than 20% of surveyed API manufacturers had detailed decarbonization implementation plans in 2023.[7]
  • 13% was AstraZeneca’s reduction in waste versus its 2015 baseline in 2024, lowering emissions associated with waste treatment.[27]

15 Statistics

Globalization & Expansion

Clinical development concentration shows through country-use concentration, with 58% of total average clinical-trial country use concentrated in the 10 most-used countries during 2021–2023.

Globalization in the biomed industry

  • 58% of total average clinical-trial country use was concentrated in the 10 most-used countries during 2021–2023.[44]
  • 16% of global clinical-trial country use came from the United States during 2021–2023, while China contributed 13%.[44]
  • 12% of the pharmaceutical development pipeline from Phase I through regulatory submission was attributed to China-headquartered companies in 2021.[44]
  • 28% of global clinical-trial starts were represented by China-headquartered companies in 2024, up from 3% a decade earlier.[44]
  • 51.8% of global pharmaceutical sales came from the United States in 2024, compared with approximately 7% from China.[27]

Cultural adaptation in the biomed industry

  • 4% of France’s cell-and-gene-therapy trials started during 2019–2023 were single-country trials.[44]
  • 94% of physicians in Lebanon reported receiving medication samples from pharmaceutical company representatives in a 2024 study.[87]
  • 23% of Australia’s cell-and-gene-therapy trials started during 2019–2023 were single-country trials.[44]
  • 10% of industry-sponsored cell-and-gene-therapy trials started in 2023 had sites in Europe, compared with 25% in 2013.[44]
  • 96% of China’s cell-and-gene-therapy trials started during 2019–2023 were single-country trials, reflecting predominantly domestic development.[44]

Supplier management in the biomed industry

  • $33 billion to $53 billion in annual U.S. healthcare-system savings were estimated from pharmaceutical-distributor services.[88]
  • 10 million essential prescription medicines and healthcare products were delivered daily by U.S. healthcare distributors to pharmacies, hospitals and other providers in 2024.[88]
  • $862 billion was the value of U.S. pharmaceutical distributor sales in 2024.[88]
  • 96% of U.S. prescription-drug sales were accounted for by pharmaceutical distributors in 2024.[88]
  • 130 strategically located distribution centers were operated by HDA members in the United States in 2024.[88]

Stakeholder management in the biomed industry

  • 37.9% of specialty-distributor sales went to hospitals in 2019 in the United States.[89]
  • 28% of clinical-trial starts were conducted in-house by large pharmaceutical companies in 2021, down from 59% in 2011.[44]
  • 39.7% of specialty-distributor sales went to hospitals in 2020 in the United States.[89]
  • 10.5% of specialty-distributor sales went to specialty pharmacies and mail-order providers in 2020 in the United States.[89]
  • 37.1% of specialty-distributor sales went to independent physician-owned or operated clinics in 2020 in the United States.[89]

Distribution channels in the biomed industry

  • 12.5% of U.S. pharmaceutical-distribution industry sales went to mail-order customers in 2023.[88]
  • 10.4% was the growth rate of U.S. traditional pharmaceutical-distribution sales in 2024.[88]
  • 93.79% of U.S. pharmaceutical products moved through wholesale distributors in the cited distribution-flow model.[90]
  • 20.4% of U.S. pharmaceutical-distribution industry sales went to hospitals, HMOs and clinics in 2023.[88]
  • 60.6% of U.S. pharmaceutical-distribution industry sales went to chain, independent and specialty pharmacies in 2023.[88]

Key questions about the biomed industry

How large is the biomedical market and what is the latest global revenue figure?
Global medical-technology revenue reached approximately $650 billion in 2025.
What growth rates should analysts track for 2025 and the first half of 2026?
Global medtech revenue increased 11% in 2025. First-half 2026 revenue rose 7.1% year over year to $325 billion.
Which companies lead the biomed industry?
Boston Scientific stands out for minimally invasive cardiovascular and specialty devices because it reports more than 48 million patients treated each year, while Roche focuses on diagnostics and biotechnology since its Diagnostics Division recorded CHF 13.8 billion sales in 2025.
What technology shifts are changing biomedical products and operations?
AI-enabled diagnostics and minimally invasive therapies are driving change, and the FDA had authorized more than 1,600 AI-enabled medical devices in the United States as of September 2026.
How is the EU biotech sector structured in terms of company size?
The EU biotechnology sector is structurally fragmented: 47% are small and medium-sized enterprises, 35% are microenterprises, and 18% are large companies.
What data and integration frictions appear repeatedly in launch and quality workflows?
In 2026, 30% of biopharma launch respondents struggled to identify the right data sources and 43% cited data latency or lack of real-time visibility.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 10). Biomed Industry Statistics. Gitnux. https://gitnux.org/biomed-industry-statistics
MLA
Samuel Norberg. "Biomed Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/biomed-industry-statistics.
Chicago
Samuel Norberg. 2026. "Biomed Industry Statistics." Gitnux. https://gitnux.org/biomed-industry-statistics.

Sources & references

106 sources cited across this report

  1. fda.gov
  2. benchling.com
  3. pmc.ncbi.nlm.nih.gov
  4. prnewswire.com
  5. eu-assets.contentstack.com
  6. ispe.org
  7. mckinsey.com
  8. nsf.org
  9. bcg.com
  10. mastercontrol.com
  11. monitor-industrial-ecosystems.ec.europa.eu
  12. veeva.com
  13. pages.awscloud.com
  14. modeln.com
  15. www-statista-com.libproxy.pcc.edu
  16. ppd.com
  17. sana-suisse-med.ch
  18. distillersr.com
  19. blog.greenlight.guru
  20. web-assets.bcg.com
  21. ey.com
  22. bio.org
  23. williamblair.com
  24. dealforma.com
  25. kpmg.com
  26. flinn.org
  27. astrazeneca.com
  28. bioutah.org
  29. novartis.com
  30. financialfilings.com
  31. marketscreener.com
  32. mddionline.com
  33. sanofi.com
  34. almirall.com
  35. cultureamp.com
  36. massbio.org
  37. cdn.pfizer.com
  38. zs.com
  39. bioinfoinc.com
  40. business.adobe.com
  41. info.amplitude.com
  42. scileads.com
  43. azonetwork.com
  44. iqvia.com
  45. wpp.com
  46. time.com
  47. bia.com
  48. emarketer.com
  49. brandirectory.com
  50. bryter-global.com
  51. s3.amazonaws.com
  52. brand-news.it
  53. media.sproutsocial.com
  54. sciencedirect.com
  55. deloitte.com
  56. link.springer.com
  57. pharmamanufacturing.com
  58. www2.deloitte.com
  59. kearney.com
  60. alirahealth.com
  61. sec.gov
  62. revenueml.com
  63. bioalberta.com
  64. advamed.org
  65. efpia.eu
  66. phrma.org
  67. gao.gov
  68. cdn.who.int
  69. 21176235.fs1.hubspotusercontent-na1.net
  70. abbviecontractmfg.com
  71. static.seitosei-presse.com
  72. bmjopen.bmj.com
  73. pubs.rsc.org
  74. oecd.org
  75. sgs.com
  76. d2e3isjppdvvam.cloudfront.net
  77. global.hisamitsu
  78. ibec.ie
  79. annualreports.com
  80. cognition.us
  81. greenlight.guru
  82. runsafesecurity.com
  83. dennemeyer.com
  84. mdic.org
  85. 2bridge.partners
  86. royaltypharma.com
  87. emro.who.int
  88. hda.org
  89. brookings.edu
  90. content.naic.org
  91. health.ec.europa.eu
  92. sebi.gov.in
  93. birac.nic.in
  94. cms.gov
  95. axios.com
  96. bostonscientific.com
  97. roche.com
  98. medtronic.com
  99. siemens-healthineers.com
  100. jnj.com
  101. stryker.com
  102. olympus-global.com
  103. jobs.thermofisher.com
  104. investor.agilent.com
  105. investor.zimmerbiomet.com
  106. healthcare.digital